SLC1A4在不同恶性肿瘤中作用的研究进展

doi:10.11904/j.issn.1002-3070.2026.01.010

Abstract

Abstract: Solute carrier family 1 member 4(SLC1A4),a neutral amino acid transporter,plays a crucial role in maintaining intracellular amino acid homeostasis,redox processes,and energy metabolism.As a ferroptosis-related gene,SLC1A4 expression is associated with poor prognosis in various malignant tumors.The SLC1A4 protein reduces the sensitivity of ferroptosis in tumor cells by regulating the uptake of cysteine and glutathione synthesis,thereby promoting the formation of chemotherapy resistance and remodeling the tumor immune microenvironment.This article reviews the role and mechanism of SLC1A4 gene in different malignant tumors,aiming to provide new targets for the diagnosis and treatment of malignant tumors.

Key words: solute carrier family 1 member 4, malignant tumors, mechanism of action, targeted therapy, ferroptosis-related genes

CLC Number:

R730.7

CAI Yihao, ZHAO Junhao, ZHAO Jinlu, LIU Ming. Research progress on the role of SLC1A4 in different malignant tumors[J]. Journal of Practical Oncology, 2026, 40(1): 69-74.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2026.01.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2026/V40/I1/69

References

1 Wu HL,Luo PF,Yan LY,et al.Research progress of amino acid transporter SLC1 family as tumor therapeutic targets [J].HJBM,2024,14(2):157-165.
2 Scalise M,Console L,Cosco J,et al.ASCT1 and ASCT2:brother and sister? [J].SLAS Discov,2021,26(9):1148-1163.
3 Lyda B,Leary G,Farnsworth J,et al.Discovery and synthesis of hydroxy-l-proline blockers of the neutral amino acid transporters SLC1A4(ASCT1)and SLC1A5(ASCT2)[J].Molecules,2024,29(10):2330-2349.
4 Liu Y,Xiong H,Yan C,et al.Bioinformatic analysis of the prognostic value of a panel of six amino acid transporters in human cancers [J].Cell J,2023,25(9):613-624.
5 Mohamed F,Ghattas M,Almansoori T,et al.Novel compound heterozygous variants(c.971delA/c.542C＞T)in SLC1A4 causes spastic tetraplegia,thin corpus callosum,and progressive microcephaly:a case report and mutational analysis [J].Front Pediatr,2023,11:1183574.
6 Stehantsev P,Stetsenko A,Nemchinova M,et al.A structural view onto disease-linked mutations in the human neutral amino acid exchanger ASCT1 [J].Comput Struct Biotechnol J,2021,19:5246-5254.
7 Pujol-Giménez J,Mirzaa G,Blue E,et al.Dominant-negative variant in SLC1A4 causes an autosomal dominant epilepsy syndrome [J].Ann Clin Transl Neurol,2023,10(6):1046-1053.
8 Odeh M,Sajrawi C,Majcher A,et al.A new type of blood-brain barrier aminoacidopathy underlies metabolic microcephaly associated with SLC1A4 mutations [J].Brain,2024,147(11):3874-3889.
9 Sarigecili E,Bulut F,Anlas O.A rare cause of microcephaly,thin corpus callosum and refractory epilepsy due to a novel SLC1A4 gene mutation [J].Clin Neurol Neurosurg,2022,218:107283.
10 Elazar D,Alvarez N,Drobeck S,et al.SLC1A4 and serine homeostasis:Implications for neurodevelopmental and neurodegenerative disorders [J].Int J Mol Sci,2025,26(5):2104.
11 Xue XF,Wang MY,Cui JT,et al.Glutathione metabolism in ferroptosis and cancer therapy [J].Cancer Lett,2025,621:217697.
12 Zhao J,Ma YB,Xia RH,et al.Skullcapflavone II inhibits SLC1A4-mediated L-serine uptake and promotes mitochondrial damage in gastric cancer [J].Adv Sci(Weinh),2025:e17225.
13 Chakraborty A,Patnaik J,Sinha A,et al.In silico analysis shows slc1a4 as a potential target of hsa-mir-133a for regulating glutamine metabolism in gastric cancer [J].Int J Biol Macromol,2024,282(Pt 5):136974.
14 Huang Y,Zou YM,Sun W,et al.Screening ferroptosis related genes influencing prognosis of gastric adenocarcinoma through bioinformatics analysis [J].Acta Med Univ Sci Technol Huazhong,2021,50(5):597-602.
15 Zheng J,Gong J.SLC1A4 promotes malignant transformation of hepatocellular carcinoma by activating the Akt signaling [J].Anal Cell Pathol(Amst),2025,2025:1115184.
16 Peng X,Chen R,Cai S,et al.SLC1A4:A powerful prognostic marker and promising therapeutic target for HCC [J].Front Oncol,2021,11:650355.
17 Yuan S,Tanzeel Y,Tian X,et al.Global analysis of HBV-mediated host proteome and ubiquitylome change in HepG2.2.15 human hepatoblastoma cell line [J].Cell Biosci,2021,11(1):75.
18 Zhang L,Ren B,Wei F,et al.Ferroptosis regulator NOS2 is closely associated with the prognosis and cell malignant behaviors of hepatoblastoma:a bioinformatic and in vitro study [J].Front Oncol,2023,13:1228199.
19 Wang H,Yang C,Jiang Y,et al.A novel ferroptosis-related gene signature for clinically predicting recurrence after hepatectomy of hepatocellular carcinoma patients [J].Am J Cancer Res,2022,12(5):1995-2011.
20 Parker S,Amendola C,Hollinshead K,et al.Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic cancer [J].Cancer Discov,2020,10(7):1018-1037.
21 Wong CH,Li CH,He Q,et al.Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma [J].Cancer Lett,2020,477:1-9.
22 Meira W,Daher B,Parks SK,et al.A cystine-cysteine intercellular shuttle prevents ferroptosis in xCT(KO)pancreatic ductal adenocarcinoma cells [J].Cancers(Basel),2021,13(6):1434.
23 Lin Z,Yang S,Qiu Q,et al.Hypoxia-induced cysteine metabolism reprogramming is crucial for the tumorigenesis of colorectal cancer [J].Redox Biol,2024,75:103286.
24 Krys D,Mattingly S,Glubrecht D,et al.PET imaging of L-Type amino acid transporter(LAT1)and cystine-glutamate antiporter(x(c)(-))with [(18)F]FDOPA and [(18)F]FSPG in breast cancer models [J].Mol Imaging Biol,2020,22(6):1562-1571.
25 Wu Z,Tang Y,Yu H,et al.The role of ferroptosis in breast cancer patients:a comprehensive analysis [J].Cell Death Discov,2021,7(1):93.
26 Li Q,Liu H,Jin Y,et al.Analysis of a new therapeutic target and construction of a prognostic model for breast cancer based on ferroptosis genes [J].Comput Biol Med,2023,165:107370.
27 Su LD,Peng JM,Bao YX,et al.Study on the role of low expression SLC1A4 in cisplatin resistance in ovarian cancer [J].Chin J Mod Appl Pharm 2024,41(9):1204-1213.
28 Xing Y,Liu Z,Ma X,et al.Targeted metabolomics analysis identified the role of FOXA1 in the change in glutamate-glutamine metabolic pattern of BaP malignantly transformed 16HBE cells [J].Toxicol Appl Pharmacol,2023,461:116402.
29 Pang S,Zhao S,Dongye Y,et al.Identification and validation of m6A-associated ferroptosis genes in renal clear cell carcinoma [J].Cell Biol Int,2024,48(6):777-794.
30 White M,Lin C,Rajapakshe K,et al.Glutamine transporters are targets of multiple oncogenic signaling pathways in prostate cancer [J].Mol Cancer Res,2017,15(8):1017-1028.
31 Ryan R,Holst J.Regulation of SLC1A4 and SLC1A5 in prostate cancer-letter [J].Mol Cancer Res,2018,16(11):1809-1810.
32 White M,Frigo D.Regulation of SLC1A4 and SLC1A5 in prostate cancer-response [J].Mol Cancer Res,2018,16(11):1811-1812.
33 Shao YF,Yu QY,Zhu JF,et al.Construction and mechanistic exploration of a ferroptosis related gene based prognostic model for cisplatin resistance in bladder cancer [J].Comput Methods Biomech Biomed Engin,2025:1-20.
34 Zhang S,Huang F,Wang Y,et al.NAT10-mediated mRNA N(4)-acetylcytidine reprograms serine metabolism to drive leukaemogenesis and stemness in acute myeloid leukaemia [J].Nat Cell Biol,2024,26(12):2168-2182.
35 Feng XY,Qin YF,Yuan Y,et al.Machine learning combined with immune cell infiltration to analyze the mechanism of ferroptosis in chronic myeloid leukemia [J].Biotechnology,2024,34(6):696-706.
36 Park HY,Lee SB,Yoo HY,et al.Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma [J].Oncotarget,2016,7(52):86433-86445.
37 Li Z,Zhang X,Jin Q,et al.Development of a macrophage-related risk model for metastatic melanoma [J].Int J Mol Sci,2023,24(18):13752.

[1]	QUAN Xinzhu, PAN Yufei, WANG Hongyang, DONG Liwei. Functional and clinical significance of protein glycosylation modification in hepatocellular [J]. Journal of Practical Oncology, 2026, 40(1): 56-63.
[2]	CHEN Mingrui, HAN Yingying, LIN Ling, DUAN Yangyang, LIU Haifeng, LIU Yun, CAI Bo, XU Hong, LI Xinlin. Analysis for the epidemic status of malignant tumors in urban areas of Nantong City in 2020 and the trend of changes from 2011 to 2020 [J]. Journal of Practical Oncology, 2025, 39(6): 500-506.
[3]	ZHAO Zhilong, HOU Junming. Research progress on the mechanism and therapeutic targets of extracellular matrix in pancreatic cancer [J]. Journal of Practical Oncology, 2025, 39(6): 535-541.
[4]	CAI Yiqing, DAI Enyong. Recent progress on molecular targeted therapy for gastric cancer [J]. Journal of Practical Oncology, 2025, 39(6): 542-550.
[5]	ZHOU Suxia, XU Zhihua, GUO Shuling, FAN Ning, XU Lili. Analysis for the prevalence trend of malignant tumor incidence and mortality in cancer registration areas in Qinghai Province from 2014 to 2021 [J]. Journal of Practical Oncology, 2025, 39(5): 381-387.
[6]	DAI Xiaoze, MA Yuxia, LI Yuting, QI Xiaoqing, ZHU Tiancen, MU Huijuan, LIU Hui. Analysis of the incidence and mortality trends of malignant tumors among urban residents in Fuxin City,Liaoning Province from 2014 to 2020 [J]. Journal of Practical Oncology, 2025, 39(4): 278-283.
[7]	ZHU Tiancen, LI Yanxia, REN Fanghan, DAI Xiaoze, LIU Yang, MU Huijuan. Analyses for the epidemic situation of malignant tumors in cancer registration areas of Liaoning Province in 2021 [J]. Journal of Practical Oncology, 2025, 39(4): 294-300.
[8]	LI Ji, ZHANG Maorong, YANG Zhao, WEN Hongmei, WU Fuxian, LI Yuntao. Analyses for the incidence and mortality characteristics of malignant tumors in the cancer registration areas of Kunming City,Yunnan Province in 2020 and their trend from 2016 to 2020 [J]. Journal of Practical Oncology, 2025, 39(3): 169-176.
[9]	WEN Xiaoyan, CHEN Li. Comparative analysis of the burden of malignant tumors among the people aged 30 and above in Sichuan province in 2010 and 2020 [J]. Journal of Practical Oncology, 2025, 39(1): 1-6.
[10]	SU Feng, LIANG Lei, DENG Ying, ZHANG Tonglei, WANG Yanping. Analysis of the epidemic characteristics and trends of cancer in Ankang city,Shaanxi province from 2016 to 2020 [J]. Journal of Practical Oncology, 2024, 38(5): 300-305.
[11]	SHAO Yuming, ZHU Kunbing, ZHANG Jie. Research progress of SP/NK-1R system in breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 268-272.
[12]	Breast Oncology Group of Heilongjiang Medical Association. Expert consensus on clinicopathological diagnosis of breast cancer with low expression of HER2 in Heilongjiang province(2024 edition) [J]. Journal of Practical Oncology, 2024, 38(2): 71-78.
[13]	ZHONG Nvjuan, MA Jingyu, XU Zhida. The incidence and mortality of malignant tumors in Fuqing city,Fujian province in 2019 and trend analysis from 2015 to 2019 [J]. Journal of Practical Oncology, 2024, 38(1): 1-6.
[14]	CHENG Jin, WANG Wei. Research progress on retinoic acid-induced proteins in malignant tumors of the digestive system [J]. Journal of Practical Oncology, 2023, 37(6): 502-506.
[15]	FAN Tingting, DING Danni, ZHAO Zixue, YU Yang, HAN Fengjuan. Fatty acid metabolism and ovarian cancer [J]. Journal of Practical Oncology, 2023, 37(5): 429-433.

Research progress on the role of SLC1A4 in different malignant tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments